Advertisement

Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs

  • Nanor Minoyan
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

    Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author
  • Andreea A. Artenie
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

    Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author
  • Geng Zang
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author
  • Didier Jutras-Aswad
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

    Department of Psychiatry and Addiction, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author
  • Marie-Ève Turcotte
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author
  • Julie Bruneau
    Correspondence
    Address correspondence to: Julie Bruneau, MD, MSc, Centre Hospitalier de l'Université de Montréal - Research Center, 900 rue Saint-Denis, R05-746, Montreal, Quebec, Canada H2X 0A9.
    Affiliations
    Research Centre of the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

    Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
    Search for articles by this author

      Introduction

      Needle and syringe programs and opioid agonist therapy are essential for harm reduction among people who inject drugs. Few studies assess their combined potential in preventing hepatitis C virus infection. No studies have assessed whether they perform similarly among individuals at risk of primary and recurrent infection. This study aimed to estimate the rates of hepatitis C virus acquisition according to harm reduction coverage among hepatitis C virus–naive and previously infected people who inject drugs in Montreal, Canada.

      Methods

      This prospective cohort study involved regular interviews and hepatitis C antibody and RNA testing (data collection: 2010–2017, analysis: 2018). Opioid agonist therapy coverage was defined by current dose: high (≥60 mg/day methadone, ≥16 mg buprenorphine), low, or none. Complete needle and syringe program coverage was defined as exclusively reporting safe needle and syringe sources (past 6 or 3 months). Combined coverage was defined as full (high-dose agonist/complete needle/syringe coverage), minimal (low-dose agonist/incomplete needle/syringe coverage), and partial (remaining combinations). Cox regression models were fit.

      Results

      A total of 106 events were observed over 1,183.1 person-years for primary and recurrent incidence rates of 10.6 (95% CI=8.0, 13.8) and 7.6 (95% CI=5.6, 9.9) per 100 years, respectively. High-dose opioid agonist therapy was associated with a 77% reduction in hepatitis C virus acquisition (hazard ratio=0.23, 95% CI=0.10, 0.50) compared with not receiving opioid agonist therapy. Needle and syringe coverage was not associated with infection rates. Estimates considering their combination reflected opioid agonist therapy coverage. Associations were similar among hepatitis C virus–naive and previously infected people who inject drugs.

      Conclusions

      High-dose opioid agonist therapy seems particularly important to reduce drug-related harms among hepatitis C virus–naive and previously infected people who inject drugs in Montreal.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • WHO
        Global health sector strategy on viral hepatitis 2016-2021.
        Published June 2016
        • MacArthur GJ
        • van Velzen E
        • Palmateer N
        • et al.
        Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
        Int J Drug Policy. 2014; 25: 34-52
        • Platt L
        • Minozzi S
        • Reed J
        • et al.
        Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
        Cochrane Database Syst Rev. 2017; 9CD012021
        • Bruneau J
        • Ahamad K
        • Goyer MÈ
        • et al.
        Management of opioid use disorders: a national clinical practice guideline.
        CMAJ. 2018; 190: E247-E257
        • Artenie AA
        • Minoyan N
        • Jacka B
        • et al.
        Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.
        CMAJ. 2019; 191: E462-E468
        • Institute of Medicine
        Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence.
        The National Academies Press, Washington, DC2007
        • Turner KM
        • Hutchinson S
        • Vickerman P
        • et al.
        The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
        Addiction. 2011; 106: 1978-1988
        • Aspinall EJ
        • Nambiar D
        • Goldberg DJ
        • et al.
        Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
        Int J Epidemiol. 2014; 43: 235-248
        • Abdul-Quader AS
        • Feelemyer J
        • Modi S
        • et al.
        Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
        AIDS Behav. 2013; 17: 2878-2892
        • Des Jarlais DC
        • Perlis T
        • Arasteh K
        • et al.
        Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.
        AIDS. 2005; 19: S20-S25
        • Grebely J
        • Dore GJ
        • Morin S
        • Rockstroh JK
        • Klein MB
        Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?.
        J Int AIDS Soc. 2017; 20: 22146
        • Fraser H
        • Martin NK
        • Brummer-Korvenkontio H
        • et al.
        Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
        J Hepatol. 2018; 68: 402-411
        • Allen EJ
        • Palmateer NE
        • Hutchinson SJ
        • Cameron S
        • Goldberg DJ
        • Taylor A
        Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
        Int J Drug Policy. 2012; 23: 346-352
        • Fraser H
        • Mukandavire C
        • Martin NK
        • et al.
        Modeling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
        Addiction. 2018; 113: 2118-2131
        • Martin NK
        • Hickman M
        • Hutchinson SJ
        • Goldberg DJ
        • Vickerman P
        Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
        Clin Infect Dis. 2013; 57: S39-S45
        • Ward Z
        • Platt L
        • Sweeney S
        • et al.
        Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?.
        Addiction. 2018; 113: 1727-1738
        • Leclerc P
        • Roy E
        • Morissette C
        • Alary M
        • Parent R
        • Blouin K
        Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection - épidémiologie du VIH de 1995 à 2016 - Épidémiologie du VHC de 2003 à 2016.
        Institut national de santé publique du Québec, Quebec, QC2018: 143
        www.inspq.qc.ca/publications/2400
        Date accessed: February 26, 2018
        • Badr G
        • Bédard N
        • Abdel-Hakeem MS
        • et al.
        Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.
        J Virol. 2008; 82: 10017-10031
        • Bruneau J
        • Daniel M
        • Abrahamowicz M
        • Zang G
        • Lamothe F
        • Vincelette J
        Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: a 16-year longitudinal study.
        Am J Epidemiol. 2011; 173: 1049-1058
        • Langendam MW
        • van Haastrecht HJ
        • van Ameijden EJ
        The validity of drug users’ self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities.
        Int J Epidemiol. 1999; 28: 514-520
        • Kampman K
        • Jarvis M
        American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use.
        J Addict Med. 2015; 9: 358-367
        • Clinical guidelines on drug misuse and dependence update 2017 Independent Expert Working Group
        Drug Misuse and Dependence: UK Guidelines on Clinical Management.
        Global and Public Health / Population Health / Health Behaviours / 25460, London, United Kingdom2017 (Published July 2017)
        • Mattick RP
        • Breen C
        • Kimber J
        • Davoli M
        Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
        Cochrane Database Syst Rev. 2014; 2CD002207
        • Therneau TM
        • Grambsch PM
        • Fleming TR
        Martingale-based residuals for survival models.
        Biometrika. 1990; 77: 147-160
        • Roy E
        • Arruda N
        • Leclerc P
        • Haley N
        • Bruneau J
        • Boivin JF
        Injection of drug residue as a potential risk factor for HCV acquisition among Montreal young injection drug users.
        Drug Alcohol Depend. 2012; 126: 246-250
        • Van Den Berg C
        • Smit C
        • Van Brussel G
        • Coutinho R
        • Prins M
        • Amsterdam Cohort
        Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
        Addiction. 2007; 102: 1454-1462
        • Palmateer N
        • Kimber J
        • Hickman M
        • Hutchinson S
        • Rhodes T
        • Goldberg D
        Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
        Addiction. 2010; 105: 844-859
        • Bell DM
        Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview.
        Am J Med. 1997; 102: 9-15
        • Hagan H
        • Pouget ER
        • Des Jarlais DC
        A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.
        J Infect Dis. 2011; 204: 74-83
        • Darke S
        Self-report among injecting drug users: a review.
        Drug Alcohol Depend. 1998; 51: 253-268
        • Simmons B
        • Saleem J
        • Hill A
        • Riley RD
        • Cooke GS
        Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis.
        Clin Infect Dis. 2016; 62: 683-694
        • Sarrazin C
        • Isakov V
        • Svarovskaia ES
        • et al.
        Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
        Clin Infect Dis. 2017; 64: 44-52
        • Weir A
        • McLeod A
        • Innes H
        • et al.
        Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
        Drug Alcohol Depend. 2016; 165: 53-60
        • Martinello M
        • Hajarizadeh B
        • Grebely J
        • Dore GJ
        • Matthews GV
        HCV cure and reinfection among people with HIV/HCV coinfection and people who inject drugs.
        Curr HIV/AIDS Rep. 2017; 14: 110-121
        • Midgard H
        • Bjøro B
        • Mæland A
        • et al.
        Hepatitis C reinfection after sustained virological response.
        J Hepatol. 2016; 64: 1020-1026